Hakko

The steep gain is ascribed to strength in drug-making unit Kyowa Hakko Kirin Co. In addition, sales got a one-off boost from a change in the business year of its Australia-based National Foods Ltd.

Kirin Books Post-Quake Loss Hiroyuki Kachi 2011

Among a bevy of dietary supplements and energy drinks aimed at healthy people, citicoline is frequently found under the brand name Cognizin, sold by Kyowa Hakko USA, a unit of Japan's Kirin Holdings.

An Energy Shot for the Brain Laura Johannes 2012

LONDON—Japanese pharmaceutical company Kyowa Hakko Kirin Co. agreed to buy Scotland's Pro Strakan Group PLC for £292 million $474 million in an effort to expand its cancer-drug business outside Japan.

Kirin Drug Unit to Buy ProStrakan of Scotland Tommy Stubbington 2011

Japan's Kyowa Hakko Kirin, a unit of Japanese beverage maker Kirin Holdings, said it will buy Scottish drug maker ProStrakan Group in a friendly all-cash deal worth £292 million $474 million, as it aims to expand its cancer drug business outside of its home country.

Business Watch 2011

Pricey ProStrakan takeover points to more M&A Kyowa Hakko Kirin Co.'s proposed £292 million $470 million takeover of troubled U.K. specialty-pharmaceutical business ProStrakan Group PLC underlines Japan's determination to enter Western pharma markets even at a top-dollar price.

Breathing Life into Spirits Deals 2011

The fronting crowd was an impenetrable wall of the shiniest corporate pins: Perpetuals and Chiefs from Winfinity, Disney, Hakko, Diamond, and several other of the Web of Nine.

Jason Stoddard, Strange and Happy » Blog Archive » Eternal Franchise, 6.1 of 31.1 2009

The company's leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist.

unknown title 2011

NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.

unknown title 2011

NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.

unknown title 2011

The company's leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist.

unknown title 2011